Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

International Journal of Pharmacology

Year: 2022  |  Volume: 18  |  Issue: 2  |  Page No.: 221 - 227

Doxofylline Combined with Budesonide Exert Obvious Therapeutic Effects on Patients with Bronchial Asthma

Li Wang, Wentao Yao, Hui Wang, Ning Xu and Minghui Chen

Abstract

Background and Objective: Bronchial asthma has become one of the global public health problems currently. This study aimed to assess the effects of doxofylline combined with budesonide on the pulmonary function of patients with bronchial asthma based on changes in the levels of T helper type 1 (Th1), Th2 and Th17 cells in peripheral blood. Materials and Methods: A total of 120 patients with bronchial asthma treated were randomly divided into experimental and control groups (n = 60). The control group received budesonide suspension inhalation therapy, while the experimental group was treated with doxofylline tablets in addition to the treatment for the control group. The disappearance time of main symptoms was recorded. Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), Peak Expiratory Flow (PEF) and the levels of Th1, Th2 and Th17 cells in peripheral blood and interferon-gamma (IFN-γ), interleukin-4 (IL-4) and IL-17 in serum were measured before and after 3 months of treatment. Results: After treatment, the disappearance time of wheezing, cough, short breath and pulmonary wheezing sound in the experimental group was significantly shorter than that in the control group (p<0.05). FVC, FEV1 and PEF in both groups rose and the experimental group had a more significant increase (p<0.05). The level of Th1 cells and Th1/Th2 rose, while those of Th2 and Th17 cells declined in both groups, especially in the experimental group (p<0.05). The serum level of IFN-γ increased, while those of IL-4 and IL-17 decreased in both groups, particularly in the experimental group (p<0.05). During treatment, the incidence rate of adverse reactions was 3.33% in both groups (p>0.05). Conclusion: Doxofylline combined with budesonide can effectively relieve the imbalances of inflammatory response and immune mechanism in patients with bronchial asthma, thus ameliorating clinical symptoms and pulmonary function.

Cited References Fulltext